The Pentagon just earmarked over $74 billion for drone dominance and counter drone technologies in t

Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A de

On June 30, 2026, Schrodinger Inc (SDGR) shares fell 6.6% today, bringing the current price to $16.2

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities ar

Morgan Stanley analyst Vikram Malhorta maintains Schrodinger (NASDAQ:SDGR) with a Equal-Weight an

Schrodinger (NASDAQ:SDGR) affirms FY2026 sales outlook from $273.000 million-$293.000 million to $27

Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.63) per share which met the analyst conse

Keybanc analyst Brandon Nispel maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers t

UBS analyst Michael Yee maintains Schrodinger (NASDAQ:SDGR) with a Neutral and lowers the price t

Schrodinger (NASDAQ:SDGR) sees FY2026 sales of $273.000 million-$293.000 million vs $301.358 million

Schrodinger (NASDAQ:SDGR) reported quarterly sales of $87.200 million which beat the analyst consens

Schrödinger, Inc. (NASDAQ:SDGR) provided an update on its progress across the business in 2025 and a

TD Cowen analyst Brendan Smith maintains Schrodinger (NASDAQ:SDGR) with a Buy and lowers the pric

Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers

UBS analyst Michael Yee initiates coverage on Schrodinger (NASDAQ:SDGR) with a Neutral rating and

B of A Securities analyst Michael Ryskin upgrades Schrodinger (NASDAQ:SDGR) from Neutral to Buy a

Schrodinger (NASDAQ:SDGR) affirms FY2025 sales outlook from $243.440 million-$257.460 million to $24

Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.57) per share which beat the analyst cons

Copernic Catalysts, Inc. (Copernic) today announced that, in collaboration with Schrödinger, Inc. (N

Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers

Goldman Sachs analyst Andrea Newkirk initiates coverage on Schrodinger (NASDAQ:SDGR) with a Neutr

-SEC Filing-SEC Filing

Morgan Stanley analyst Vikram Malhorta maintains Schrodinger (NASDAQ:SDGR) with a Equal-Weight an

Citigroup analyst David Lebowitz downgrades Schrodinger (NASDAQ:SDGR) from Buy to Neutral and low

Barclays analyst Peter Lawson initiates coverage on Schrodinger (NASDAQ:SDGR) with a Overweight r

Schrodinger (NASDAQ:SDGR) affirms FY2025 sales outlook from $243.44 million-$257.46 million to $243.

Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.65) per share which beat the analyst cons

Keybanc analyst Aleksey Yefremov maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers

Schrödinger, Inc. (NASDAQ:SDGR) today announced encouraging initial clinical data from its ongoing P

Company to host webcast to review data on Thursday, June 12, 2025 at 8:00 a.m. ETSchrödinger, Inc. (

Schrodinger (NASDAQ:SDGR) Software revenue growth is expected to range from 10% to 15%; Drug discove

Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.64) per share which beat the analyst cons

Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and raises

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective an

Several stocks in the health care technology space are moving higher after the market close on Thurs

Piper Sandler analyst Joseph Catanzaro maintains Schrodinger (NASDAQ:SDGR) with a Overweight and

Schrodinger (NASDAQ:SDGR) sees FY2025 sales of $243.402 million-$257.420 million vs $265.80 million